JP2020507571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507571A5 JP2020507571A5 JP2019543051A JP2019543051A JP2020507571A5 JP 2020507571 A5 JP2020507571 A5 JP 2020507571A5 JP 2019543051 A JP2019543051 A JP 2019543051A JP 2019543051 A JP2019543051 A JP 2019543051A JP 2020507571 A5 JP2020507571 A5 JP 2020507571A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- seq
- inhibitor
- lag3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 57
- 102000036639 antigens Human genes 0.000 claims description 57
- 108091007433 antigens Proteins 0.000 claims description 57
- 239000003112 inhibitor Substances 0.000 claims description 57
- 239000012634 fragment Substances 0.000 claims description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 239000000562 conjugate Substances 0.000 claims description 20
- 230000000259 anti-tumor effect Effects 0.000 claims description 19
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 17
- 101100510618 Homo sapiens LAG3 gene Proteins 0.000 claims description 16
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 16
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims description 16
- 238000003556 assay Methods 0.000 claims description 16
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 16
- 229940127121 immunoconjugate Drugs 0.000 claims description 13
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 229960004397 cyclophosphamide Drugs 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 8
- 239000000611 antibody drug conjugate Substances 0.000 claims description 8
- 239000000539 dimer Substances 0.000 claims description 8
- 238000003384 imaging method Methods 0.000 claims description 8
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 8
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 8
- 239000000178 monomer Substances 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 229960003852 atezolizumab Drugs 0.000 claims description 6
- 229950002916 avelumab Drugs 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 229950009791 durvalumab Drugs 0.000 claims description 6
- 229960002621 pembrolizumab Drugs 0.000 claims description 6
- -1 temozolomid Chemical compound 0.000 claims description 6
- 238000002600 positron emission tomography Methods 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 4
- 102100034608 Angiopoietin-2 Human genes 0.000 claims description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 4
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 4
- 108090000172 Interleukin-15 Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 4
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940022399 cancer vaccine Drugs 0.000 claims description 4
- 238000009566 cancer vaccine Methods 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 190000008236 carboplatin Chemical compound 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 230000003013 cytotoxicity Effects 0.000 claims description 4
- 231100000135 cytotoxicity Toxicity 0.000 claims description 4
- 229960003901 dacarbazine Drugs 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 230000008472 epithelial growth Effects 0.000 claims description 4
- 230000001605 fetal effect Effects 0.000 claims description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- 108010074108 interleukin-21 Proteins 0.000 claims description 4
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 229960000639 pazopanib Drugs 0.000 claims description 4
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 4
- 229960003876 ranibizumab Drugs 0.000 claims description 4
- 229960004641 rituximab Drugs 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 229960003787 sorafenib Drugs 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 3
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 229940125555 TIGIT inhibitor Drugs 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 claims description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 2
- 229940125563 LAG3 inhibitor Drugs 0.000 claims description 2
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 claims description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000958 deferoxamine Drugs 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 2
- 230000004807 localization Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000036281 parasite infection Effects 0.000 claims 1
- 238000003325 tomography Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 230000001826 anti-prostatic effect Effects 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457287P | 2017-02-10 | 2017-02-10 | |
| US62/457,287 | 2017-02-10 | ||
| PCT/US2018/017525 WO2018148476A1 (en) | 2017-02-10 | 2018-02-09 | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020507571A JP2020507571A (ja) | 2020-03-12 |
| JP2020507571A5 true JP2020507571A5 (OSRAM) | 2021-03-25 |
| JP7167041B2 JP7167041B2 (ja) | 2022-11-08 |
Family
ID=61244834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543051A Active JP7167041B2 (ja) | 2017-02-10 | 2018-02-09 | 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10905784B2 (OSRAM) |
| EP (1) | EP3580238A1 (OSRAM) |
| JP (1) | JP7167041B2 (OSRAM) |
| KR (2) | KR102813603B1 (OSRAM) |
| CN (2) | CN118557758A (OSRAM) |
| AU (2) | AU2018219909B2 (OSRAM) |
| BR (1) | BR112019016336A2 (OSRAM) |
| CA (1) | CA3053348A1 (OSRAM) |
| CL (1) | CL2019002264A1 (OSRAM) |
| CO (1) | CO2019008675A2 (OSRAM) |
| EA (1) | EA201991673A1 (OSRAM) |
| IL (2) | IL313695A (OSRAM) |
| MA (2) | MA46814B2 (OSRAM) |
| MX (2) | MX2019009565A (OSRAM) |
| MY (1) | MY200034A (OSRAM) |
| PH (1) | PH12019501837A1 (OSRAM) |
| SG (1) | SG11201907208XA (OSRAM) |
| WO (1) | WO2018148476A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| MY200034A (en) | 2017-02-10 | 2023-12-05 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| PT3631454T (pt) | 2017-05-30 | 2023-11-23 | Bristol Myers Squibb Co | Tratamento de tumores positivos para lag-3 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| SG11202111262XA (en) | 2019-05-13 | 2021-11-29 | Regeneron Pharma | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| KR20220152555A (ko) * | 2020-03-12 | 2022-11-16 | 비온드 바이오로직스 엘티디 | 증가된 안정성을 가진 쉐딩 차단제 |
| IL299245A (en) | 2020-06-22 | 2023-02-01 | Ngm Biopharmaceuticals Inc | LAIR-1 binding agents and methods of using them |
| US12447218B1 (en) * | 2021-02-09 | 2025-10-21 | Actinium Pharmaceuticals, Inc. | Radioconjugates directed to MHC-complexed antigens in cancer |
| CN115337413B (zh) * | 2022-08-08 | 2023-08-22 | 中国科学院近代物理研究所 | 一种针对非小细胞肺癌诊断的放射性分子探针的制备及应用 |
| KR102759386B1 (ko) * | 2022-08-11 | 2025-01-24 | 성균관대학교산학협력단 | 89Zr 표지된 항-CD25 항체를 이용한 immuno-PET |
| US20240299601A1 (en) | 2023-02-17 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| IL323023A (en) | 2023-03-13 | 2025-10-01 | Regeneron Pharma | Combination of PD-1 and LAG-3 inhibitors for improved efficacy in melanoma treatment |
| TW202535926A (zh) * | 2023-10-30 | 2025-09-16 | 美商再生元醫藥公司 | 穩定抗體配製物 |
| WO2025106736A2 (en) | 2023-11-15 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US5332567A (en) | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
| US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5428156A (en) | 1993-04-02 | 1995-06-27 | Associated Universities, Inc. | Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging |
| CN1110557C (zh) | 1994-05-06 | 2003-06-04 | 古斯达威罗斯研究所 | Lag－3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体 |
| JP2000508226A (ja) | 1995-07-21 | 2000-07-04 | アプライド リサーチ システムズ アース ホールディング エヌ．ヴィ． | Ｌａｇ−３タンパク質によるｔｈ１リンパ球を検出、同定、単離並びに選択的に標識およびターゲッティングする方法 |
| US6524802B1 (en) * | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
| EP0900841A1 (en) | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1487879B1 (en) | 2002-03-01 | 2012-12-26 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| ES2439580T5 (en) | 2003-02-28 | 2025-01-23 | Univ Johns Hopkins | T cell regulation |
| US7199064B2 (en) | 2003-09-08 | 2007-04-03 | Matsushita Electric Industrial Co., Ltd. | Plasma processing method and apparatus |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| US20100111856A1 (en) * | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| WO2006049599A1 (en) | 2004-10-28 | 2006-05-11 | The General Hospital Corporation | Methods of detection and therapy for atheromatous plaques using immune modulation |
| WO2006050058A2 (en) | 2004-10-28 | 2006-05-11 | The General Hospital Corporation | Methods of detection and therapy of inflamed tissues using immune modulation |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| NZ573557A (en) | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| US8889100B2 (en) | 2007-01-11 | 2014-11-18 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| WO2008124467A1 (en) | 2007-04-06 | 2008-10-16 | Macrocyclics | Bifunctional hydroxamic acid ligands and method of synthesis |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US20090297439A1 (en) | 2008-06-02 | 2009-12-03 | Metheresis Translational Research Sa, | Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| SI2975051T1 (sl) | 2009-06-26 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom |
| DK2505654T4 (da) | 2010-02-08 | 2020-07-27 | Regeneron Pharma | Mus med fælles letkæde |
| NZ602840A (en) | 2010-06-03 | 2014-11-28 | Genentech Inc | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
| EP3296321B1 (en) | 2010-12-20 | 2020-07-15 | F. Hoffmann-La Roche AG | Anti-mesothelin antibodies and immunoconjugates |
| MY172718A (en) | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
| EP2800587A2 (en) | 2012-01-06 | 2014-11-12 | LinXis B.V. | Method for preparing cell targeting conjugates, and the complexes obtained |
| WO2013138696A1 (en) | 2012-03-16 | 2013-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Zirconium-89 complexes, methods of labeling cells, labeled cells, kits, and methods of use thereof |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| SG11201407106XA (en) | 2012-05-01 | 2014-11-27 | Genentech Inc | Anti-pmel17 antibodies and immunoconjugates |
| TWI614265B (zh) | 2012-05-21 | 2018-02-11 | 建南德克公司 | 抗－Ｌｙ６Ｅ抗體及免疫結合物及其使用方法 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| US20150191543A1 (en) | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| WO2014066733A2 (en) | 2012-10-25 | 2014-05-01 | Life Technologies Corporation | Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins |
| EP2740726A1 (en) | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin receptor ligands |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| WO2014133093A1 (ja) | 2013-02-28 | 2014-09-04 | 独立行政法人国立がん研究センター | 不溶性フィブリンに対する抗体 |
| US20140271462A1 (en) | 2013-03-13 | 2014-09-18 | Imaginab, Inc. | Antigen binding constructs to cd8 |
| KR20150127199A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 항-b7-h4 항체 및 면역접합체 |
| US20160000946A1 (en) | 2013-03-14 | 2016-01-07 | The Board Of Trustees Of The Leland Stanford Junior University | Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma |
| HUE049957T2 (hu) | 2013-03-15 | 2020-11-30 | Glaxosmithkline Ip Dev Ltd | Lag-3 elleni kötõfehérjék |
| US20170035917A1 (en) | 2013-06-10 | 2017-02-09 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| FR3008408B1 (fr) | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
| LT3041507T (lt) | 2013-08-26 | 2021-08-25 | Biontech Research And Development, Inc. | Nukleorūgštys, koduojančios antikūnus prieš sialil-lewis a |
| PL3508502T3 (pl) | 2013-09-20 | 2023-07-17 | Bristol-Myers Squibb Company | Kombinacja przeciwciał anty-lag-3 i przeciwciał anty-pd-1 w leczeniu raka |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| KR20160068963A (ko) | 2013-10-21 | 2016-06-15 | 제넨테크, 인크. | 항-Ly6E 항체 및 사용 방법 |
| BR112016011025B1 (pt) | 2013-11-19 | 2024-01-23 | Fredax Ab | Polipeptídeos anticorpo com especificidade de ligação para calicreina-2 humana (hk2), composição farmacêutica que os compreende e molécula de ácido nucleico |
| TW201533060A (zh) | 2013-12-13 | 2015-09-01 | Genentech Inc | 抗ｃｄ３３抗體及免疫結合物 |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| CN106459199B (zh) * | 2014-03-11 | 2021-01-01 | 瑞泽恩制药公司 | 抗-egfrviii抗体及其用途 |
| LT3116909T (lt) | 2014-03-14 | 2020-02-10 | Novartis Ag | Antikūno molekulės prieš lag-3 ir jų panaudojimas |
| DK3131585T3 (da) | 2014-03-19 | 2020-10-19 | Univ Zuerich | Multidentate, bifunktionelle chelateringsmidler til radionuklidkompleksdannelse i diagnostik og terapi |
| WO2015179658A2 (en) | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
| EP2954933A1 (en) | 2014-06-10 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand |
| AU2015273934B2 (en) | 2014-06-10 | 2020-08-20 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| MX2016016233A (es) | 2014-06-11 | 2017-03-31 | Genentech Inc | Anticuerpos anti-lgr5 y sus usos. |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| ES2819451T3 (es) | 2014-08-08 | 2021-04-16 | Univ Leland Stanford Junior | Agentes PD-1 de alta afinidad y procedimientos de uso |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| EA201790569A1 (ru) | 2014-09-12 | 2017-08-31 | Дженентек, Инк. | Антитела и иммуноконъюгаты против cll-1 |
| SG11201701623UA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Anti-her2 antibodies and immunoconjugates |
| JP6943760B2 (ja) | 2014-09-12 | 2021-10-06 | ジェネンテック， インコーポレイテッド | 抗ｂ７−ｈ４抗体及び免疫複合体 |
| ES2980073T3 (es) | 2014-10-16 | 2024-09-27 | Univ Melbourne | Composición novedosa de diagnóstico por imágenes y usos de la misma |
| ES2822990T3 (es) | 2014-11-25 | 2021-05-05 | Bristol Myers Squibb Co | Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| US11534506B2 (en) | 2015-03-06 | 2022-12-27 | Mayo Foundation For Medical Education And Research | Methods for cell labeling and medical imaging |
| NL2014423B1 (en) | 2015-03-09 | 2016-10-13 | Linxis B V | Method for removing weakly bound functional moieties from cell targeting conjugates. |
| KR20180004740A (ko) | 2015-04-20 | 2018-01-12 | 이펙터 테라퓨틱스, 인크. | 암 및 감염 치료에 사용하기 위한 면역 체크포인트 조절 인자의 억제제 |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| CA2993177A1 (en) | 2015-07-22 | 2017-01-26 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind lag3 |
| CN106699888B (zh) | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| US20170097333A1 (en) | 2015-09-28 | 2017-04-06 | Merck Sharp & Dohme Corp. | Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents |
| US12048753B2 (en) | 2015-10-01 | 2024-07-30 | Whitehead Institute For Biomedical Research | Labeling of antibodies |
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| MA43260A (fr) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Liants pd1 et/ou lag3 |
| WO2017087826A1 (en) | 2015-11-18 | 2017-05-26 | Memorial Sloan Kettering Cancer Center | Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods |
| EP3377533A2 (en) | 2015-11-19 | 2018-09-26 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
| MA43576A (fr) | 2015-12-16 | 2018-11-14 | Merck Sharp & Dohme | Anticorps anti-lag3 et fragments de fixation à l'antigène |
| SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
| IL262892B2 (en) | 2016-05-18 | 2024-04-01 | Boehringer Ingelheim Int | Anti pd-1 and anti-lag3 antibodies for cancer treatment |
| SMT202100238T1 (it) | 2016-05-19 | 2021-05-07 | Bristol Myers Squibb Co | Immunomodulatori per l'indagine per immagini mediante pet |
| EP3463578A1 (en) | 2016-06-06 | 2019-04-10 | LinXis B.V. | Cell targeting conjugates |
| EP3472207B1 (en) | 2016-06-20 | 2021-01-20 | F-Star Delta Limited | Binding molecules binding pd-l1 and lag-3 |
| TWI757304B (zh) | 2016-06-23 | 2022-03-11 | 大陸商江蘇恆瑞醫藥股份有限公司 | Lag-3抗體、其抗原結合片段及其醫藥用途 |
| AU2017281940C1 (en) | 2016-06-24 | 2024-11-07 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| EP3266465A1 (en) | 2016-07-06 | 2018-01-10 | Julius-Maximilians-Universität Würzburg | Immune complexes |
| KR102396334B1 (ko) | 2016-07-18 | 2022-05-09 | 위스콘신 얼럼나이 리서어치 화운데이션 | 인 시츄 면역 조절 암 백신화를 위한 방사성할로겐화 제제 |
| US11633506B2 (en) | 2016-07-18 | 2023-04-25 | Wisconsin Alumni Research Foundation | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies |
| US11168148B2 (en) | 2016-09-07 | 2021-11-09 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
| PT3515946T (pt) * | 2016-09-23 | 2022-08-04 | Regeneron Pharma | Anticorpos anti-muc16 (mucin 16) |
| WO2018058125A1 (en) | 2016-09-26 | 2018-03-29 | Ensemble Group Holdings | Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems |
| US11103603B2 (en) | 2016-10-20 | 2021-08-31 | The University Of North Carolina At Chapel Hill | 18F-labeled compounds for PET imaging and uses thereof |
| US11266639B2 (en) | 2016-11-07 | 2022-03-08 | Vidac Pharma Ltd. | Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers |
| MX2019006131A (es) * | 2016-11-29 | 2019-08-21 | Regeneron Pharma | Metodos para tratar cancer de mama positivo para prlr. |
| MA46952A (fr) * | 2016-12-01 | 2019-10-09 | Regeneron Pharma | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet |
| WO2018107178A1 (en) | 2016-12-09 | 2018-06-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods for sequencing t cell receptors and uses thereof |
| MY200034A (en) | 2017-02-10 | 2023-12-05 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| EP4589014A3 (en) | 2017-09-20 | 2025-10-15 | Regeneron Pharmaceuticals, Inc. | Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden |
-
2018
- 2018-02-09 MY MYPI2019004493A patent/MY200034A/en unknown
- 2018-02-09 IL IL313695A patent/IL313695A/en unknown
- 2018-02-09 AU AU2018219909A patent/AU2018219909B2/en active Active
- 2018-02-09 CN CN202410383516.2A patent/CN118557758A/zh active Pending
- 2018-02-09 US US15/892,440 patent/US10905784B2/en active Active
- 2018-02-09 CN CN201880024346.1A patent/CN110650974B/zh active Active
- 2018-02-09 EA EA201991673A patent/EA201991673A1/ru unknown
- 2018-02-09 BR BR112019016336-0A patent/BR112019016336A2/pt unknown
- 2018-02-09 SG SG11201907208XA patent/SG11201907208XA/en unknown
- 2018-02-09 CA CA3053348A patent/CA3053348A1/en active Pending
- 2018-02-09 JP JP2019543051A patent/JP7167041B2/ja active Active
- 2018-02-09 KR KR1020247013269A patent/KR102813603B1/ko active Active
- 2018-02-09 EP EP18706165.0A patent/EP3580238A1/en active Pending
- 2018-02-09 MA MA46814A patent/MA46814B2/fr unknown
- 2018-02-09 KR KR1020197026079A patent/KR102660715B1/ko active Active
- 2018-02-09 IL IL268667A patent/IL268667B2/en unknown
- 2018-02-09 WO PCT/US2018/017525 patent/WO2018148476A1/en not_active Ceased
- 2018-02-09 MX MX2019009565A patent/MX2019009565A/es unknown
- 2018-02-09 MA MA047456A patent/MA47456A/fr unknown
-
2019
- 2019-08-08 PH PH12019501837A patent/PH12019501837A1/en unknown
- 2019-08-09 CO CO2019008675A patent/CO2019008675A2/es unknown
- 2019-08-09 CL CL2019002264A patent/CL2019002264A1/es unknown
- 2019-08-09 MX MX2025004620A patent/MX2025004620A/es unknown
-
2020
- 2020-12-18 US US17/127,618 patent/US11511001B2/en active Active
-
2022
- 2022-10-25 US US18/049,609 patent/US20230270894A1/en active Pending
-
2025
- 2025-02-11 AU AU2025200923A patent/AU2025200923A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020507571A5 (OSRAM) | ||
| JP2020534250A5 (OSRAM) | ||
| JP2020512281A5 (OSRAM) | ||
| JP2021531764A5 (OSRAM) | ||
| JP7126941B2 (ja) | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ | |
| JP2020103301A5 (OSRAM) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| JP2020528750A5 (OSRAM) | ||
| JPWO2019246514A5 (OSRAM) | ||
| JP2018532383A5 (OSRAM) | ||
| JP2022513053A (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| JP2017535257A5 (OSRAM) | ||
| JP2019531084A5 (OSRAM) | ||
| JP2019534034A5 (OSRAM) | ||
| JP2020515247A5 (OSRAM) | ||
| JP2018512170A5 (OSRAM) | ||
| US20240197931A1 (en) | Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells | |
| JP2020501598A5 (OSRAM) | ||
| JP2019510733A5 (OSRAM) | ||
| JPWO2020135201A5 (OSRAM) | ||
| JP2015535828A5 (OSRAM) | ||
| JP2017500057A5 (OSRAM) | ||
| RU2015129551A (ru) | Антитела к в7-н4 человека и их применение | |
| JP2018508214A5 (OSRAM) | ||
| EP3442576A1 (en) | High affinity b7-h6 antibodies and antibody fragments |